$HRMY
Harmony Biosciences Holdings Inc

2021 Q2 Form 10-Q Financial Statement

#000156459021042897 Filed on August 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2 2020 Q1
Revenue $73.82M $38.01M $19.84M
YoY Change 94.24%
Cost Of Revenue $12.69M $6.456M $3.470M
YoY Change 96.51%
Gross Profit $61.13M $31.55M $16.37M
YoY Change 93.77%
Gross Profit Margin 82.81% 83.01% 82.49%
Selling, General & Admin $31.32M $20.07M $22.54M
YoY Change 56.07%
% of Gross Profit 51.24% 63.62% 137.75%
Research & Development $6.498M $4.169M $3.431M
YoY Change 55.86%
% of Gross Profit 10.63% 13.21% 20.96%
Depreciation & Amortization $4.728M $1.990M $97.00K
YoY Change 137.59% 847.62%
% of Gross Profit 7.73% 6.31% 0.59%
Operating Expenses $37.82M $24.24M $25.98M
YoY Change 56.03%
Operating Profit $23.31M $7.309M -$9.609M
YoY Change 218.95%
Interest Expense -$7.227M -$6.936M -$6.372M
YoY Change 4.2%
% of Operating Profit -31.0% -94.9%
Other Income/Expense, Net $4.000K -$400.0K $0.00
YoY Change -101.0%
Pretax Income $16.09M -$27.00K -$38.62M
YoY Change -59688.89%
Income Tax $1.972M $0.00 $0.00
% Of Pretax Income 12.26%
Net Earnings $14.12M -$27.00K -$38.62M
YoY Change -52385.19%
Net Earnings / Revenue 19.12% -0.07% -194.66%
Basic Earnings Per Share $0.25 -$1.34 -$6.30
Diluted Earnings Per Share $0.24 -$1.34 -$6.30
COMMON SHARES
Basic Shares Outstanding 56.94M 7.806M 7.791M
Diluted Shares Outstanding 58.59M 7.806M 7.791M

Balance Sheet

Concept 2021 Q2 2020 Q2 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $159.7M $76.30M
YoY Change 109.29%
Cash & Equivalents $159.7M $77.03M $72.27M
Short-Term Investments
Other Short-Term Assets $1.559M $4.700M
YoY Change -66.83%
Inventory $4.951M $2.100M
Prepaid Expenses $7.322M
Receivables $31.20M $15.20M
Other Receivables $0.00 $0.00
Total Short-Term Assets $204.7M $98.30M
YoY Change 108.25%
LONG-TERM ASSETS
Property, Plant & Equipment $944.0K $1.100M
YoY Change -14.18%
Goodwill
YoY Change
Intangibles $153.1M
YoY Change
Long-Term Investments
YoY Change
Other Assets $152.0K $900.0K
YoY Change -83.11%
Total Long-Term Assets $155.0M $70.50M
YoY Change 119.83%
TOTAL ASSETS
Total Short-Term Assets $204.7M $98.30M
Total Long-Term Assets $155.0M $70.50M
Total Assets $359.7M $168.8M
YoY Change 113.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.006M $2.100M
YoY Change -4.48%
Accrued Expenses $26.65M $19.00M
YoY Change 40.28%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $36.60M $21.10M
YoY Change 73.44%
LONG-TERM LIABILITIES
Long-Term Debt $195.6M $192.5M
YoY Change 1.62%
Other Long-Term Liabilities $939.0K $4.600M
YoY Change -79.59%
Total Long-Term Liabilities $196.5M $197.1M
YoY Change -0.28%
TOTAL LIABILITIES
Total Short-Term Liabilities $36.60M $21.10M
Total Long-Term Liabilities $196.5M $197.1M
Total Liabilities $233.1M $218.2M
YoY Change 6.85%
SHAREHOLDERS EQUITY
Retained Earnings -$466.7M
YoY Change
Common Stock $593.2M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $126.6M -$483.4M -$472.3M
YoY Change
Total Liabilities & Shareholders Equity $359.7M $168.8M
YoY Change 113.09%

Cashflow Statement

Concept 2021 Q2 2020 Q2 2020 Q1
OPERATING ACTIVITIES
Net Income $14.12M -$27.00K -$38.62M
YoY Change -52385.19%
Depreciation, Depletion And Amortization $4.728M $1.990M $97.00K
YoY Change 137.59% 847.62%
Cash From Operating Activities $18.07M $4.830M -$26.70M
YoY Change 274.12% -117.25%
INVESTING ACTIVITIES
Capital Expenditures -$205.0K $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities -$205.0K $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 650.0K -60.00K 73.76M
YoY Change -1183.33% -100.08%
NET CHANGE
Cash From Operating Activities 18.07M 4.830M -26.70M
Cash From Investing Activities -205.0K 0.000 0.000
Cash From Financing Activities 650.0K -60.00K 73.76M
Net Change In Cash 18.52M 4.770M 47.06M
YoY Change 288.16% -164.55%
FREE CASH FLOW
Cash From Operating Activities $18.07M $4.830M -$26.70M
Capital Expenditures -$205.0K $0.00 $0.00
Free Cash Flow $18.28M $4.830M -$26.70M
YoY Change 278.36% -117.3%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
CY2021Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
153135000
CY2021Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
195610000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
194250000
CY2021Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
939000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1105000
CY2021Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
196549000
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
195355000
CY2021Q2 us-gaap Liabilities
Liabilities
233144000
CY2020Q4 us-gaap Liabilities
Liabilities
329894000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-488195000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
97180000
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Address Address Line3
EntityAddressAddressLine3
Suite 215
dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
228631000
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Document Type
DocumentType
10-Q
dei Entity Registrant Name
EntityRegistrantName
HARMONY BIOSCIENCES HOLDINGS, INC.
dei Entity Address Address Line2
EntityAddressAddressLine2
Germantown Pike
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Shell Company
EntityShellCompany
false
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
CY2020Q4 us-gaap Inventory Net
InventoryNet
3823000
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2279923
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39450
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Address Address Line1
EntityAddressAddressLine1
630 W.
dei Entity Address City Or Town
EntityAddressCityOrTown
Plymouth Meeting
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19462
dei City Area Code
CityAreaCode
484
dei Local Phone Number
LocalPhoneNumber
539-9800
dei Security12b Title
Security12bTitle
Common Stock, par value $0.00001 value per share
dei Trading Symbol
TradingSymbol
HRMY
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1302000
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
57008474
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
159686000
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
6959000
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
31196000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
22176000
CY2021Q2 us-gaap Inventory Net
InventoryNet
4951000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
262891000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
938000
CY2021Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
7322000
CY2021Q2 us-gaap Other Assets Current
OtherAssetsCurrent
1559000
CY2021Q2 us-gaap Assets Current
AssetsCurrent
204714000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
944000
CY2020Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1217
CY2020Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.12
CY2020Q3 hrmy Preferred Stock Conversion Ratio
PreferredStockConversionRatio
0.1217
CY2020Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1217
CY2020Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.12
CY2020Q3 hrmy Preferred Stock Conversion Ratio
PreferredStockConversionRatio
0.1217
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M17D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y5M19D
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.5500
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0066
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0032
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.9580
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0119
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0056
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2020Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
164183000
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
57000139
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
57000139
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
56890569
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
56890569
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
1000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
593242000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
585374000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-466692000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
126551000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
359695000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
73821000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
38005000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
152000
CY2021Q2 us-gaap Assets
Assets
359695000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
162343000
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
152000
CY2021Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
154981000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
122727000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2556000
CY2020Q4 us-gaap Assets
Assets
427074000
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2006000
CY2021Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
6043000
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
8942000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
26653000
CY2021Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1893000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
314000
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
36595000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
134539000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
133495000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-59538000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
57845000
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
12687000
CY2020Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6456000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
427074000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
23097000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
9930000
CY2021Q2 us-gaap Gross Profit
GrossProfit
61134000
CY2020Q2 us-gaap Gross Profit
GrossProfit
31549000
us-gaap Gross Profit
GrossProfit
110398000
us-gaap Gross Profit
GrossProfit
47915000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6498000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4169000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11177000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7600000
CY2021Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
17022000
CY2020Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
12443000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
32529000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
25697000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14302000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7628000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28848000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15772000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
37822000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
24240000
us-gaap Operating Expenses
OperatingExpenses
72554000
us-gaap Operating Expenses
OperatingExpenses
49069000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
23312000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
7309000
us-gaap Operating Income Loss
OperatingIncomeLoss
37844000
us-gaap Operating Income Loss
OperatingIncomeLoss
-1154000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-22639000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4000
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-400000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-15000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1546000
CY2021Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-7227000
CY2020Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-6936000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-14354000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-13308000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
16089000
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-27000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
23475000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-38647000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1972000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1972000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
14117000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-27000
us-gaap Net Income Loss
NetIncomeLoss
21503000
us-gaap Net Income Loss
NetIncomeLoss
-38647000
CY2020Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
10446000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
20891000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
14117000
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10473000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
21503000
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.63
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.34
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.37
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.34
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.38
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.24
CY2020Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
318510205
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.63
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56940840
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7805848
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56916282
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7798928
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58592876
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7805848
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58635195
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7798928
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
97180000
us-gaap Net Income Loss
NetIncomeLoss
21503000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
660000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7208000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
126551000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
107879000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
14117000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
648000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3907000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
126551000
CY2019Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
318510205
CY2019Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
411275000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-422862000
us-gaap Net Income Loss
NetIncomeLoss
-38647000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
251000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
797000
us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
167000
CY2020Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
434009000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-483362000
CY2020Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
318510205
CY2020Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
422642000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-472330000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-27000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
100000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
429000
CY2020Q2 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
167000
CY2020Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
318510205
CY2020Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
434009000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-483362000
us-gaap Profit Loss
ProfitLoss
21503000
us-gaap Profit Loss
ProfitLoss
-38647000
us-gaap Depreciation
Depreciation
200000
us-gaap Depreciation
Depreciation
194000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
9208000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3693000
us-gaap Share Based Compensation
ShareBasedCompensation
7208000
us-gaap Share Based Compensation
ShareBasedCompensation
797000
hrmy Stock Appreciation Rights Market Adjustment
StockAppreciationRightsMarketAdjustment
-130000
hrmy Stock Appreciation Rights Market Adjustment
StockAppreciationRightsMarketAdjustment
139000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1584000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1361000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
680000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-22639000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
9019000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
10984000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1128000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
228631000
CY2021Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
995000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
622000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2987000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-789000
hrmy Cash Paid For Milestones
CashPaidForMilestones
100000000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
167000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
660000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
73695000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-68945000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
51823000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
229381000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25207000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
160436000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
77030000
us-gaap Interest Paid Net
InterestPaidNet
13092000
us-gaap Interest Paid Net
InterestPaidNet
12698000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-550000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-4287000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2606000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
5456000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-37000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
59000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
30600000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21870000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
205000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
100000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-100205000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
200000000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
5804000
us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
102538000
hrmy Payments Of Extinguishment Of Debt Exit Fees
PaymentsOfExtinguishmentOfDebtExitFees
-18047000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
660000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
251000
hrmy Warrant Financing
WarrantFinancing
2359000
CY2020Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
410239
CY2020Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-8.215
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-466692000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-488195000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
159686000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
229381000
us-gaap Finite Lived Intangible Assets Remaining Amortization Period1
FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
P8Y3M
CY2021Q1 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P9Y
us-gaap Finite Lived Intangible Assets Remaining Amortization Period1
FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
P8Y3M
CY2020Q4 us-gaap Inventory Net
InventoryNet
3823000
CY2019Q4 hrmy License Agreement Milestone Payments Paid
LicenseAgreementMilestonePaymentsPaid
75000000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
160436000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.77%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosures in the <span style="Background-color:#FFFFFF;">Condensed</span> Consolidated Financial Statements, including the notes thereto, and elsewhere in this report. Uncertainties related to the magnitude and duration of COVID-19, the extent to which it will impact our estimated future financial results, worldwide macroeconomic conditions including interest rates, employment rates, consumer spending and health insurance coverage, the speed of the anticipated recovery and governmental and business reactions to the pandemic have increased the complexity of developing these estimates, including the carrying amounts of long-lived assets, and the intangible asset. Actual results may differ significantly from our estimates, including as a result of COVID-19.</p>
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
159686000
CY2020Q4 us-gaap Inventory Gross
InventoryGross
3997000
CY2021Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
135000
CY2020Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
174000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentrations of Risk </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Substantially all of the Company’s cash and money market funds are held with a single financial institution. Due to its size, the Company believes this financial institution represents minimal credit risk. Deposits in this institution may exceed the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation for U.S. institutions. The Company has not experienced any losses on its deposits of cash and cash equivalents. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is also subject to credit risk from its trade receivables related to its product sales. The Company monitors its exposure within accounts receivable and records a reserve against uncollectible accounts receivable as necessary. The Company extends credit to specialty pharmaceutical distribution companies within the United States. Customer creditworthiness is monitored and collateral is not required. Historically, the Company has not experienced credit losses on its accounts receivable. As of June 30, 2021, three customers accounted for 100% of gross accounts receivable; Caremark LLC (“CVS Caremark”), which accounted for 35% of gross accounts receivable; PANTHERx Specialty Pharmacy LLC (“Pantherx”), which accounted for 35% of gross accounts receivable; and Accredo Health Group, Inc. (“Accredo”), which accounted for 30% of gross accounts receivable. As of December 31, 2020, three customers accounted for 100% of gross accounts receivable; CVS Caremark, which accounted for 44% of gross accounts receivable; Pantherx, which accounted for 23% of gross accounts receivable; and Accredo, which accounted for 33% of gross accounts receivable.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.61%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the six months ended June 30, 2021, three customers accounted for 100% of gross product revenues; CVS Caremark accounted for 37% of gross product revenues; Pantherx accounted for 35% of gross product </p> <p style="margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">revenues; and Accredo accounted for </span>28<span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of gross product revenues.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">six </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">months</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> ended </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 30</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2020</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">three</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> customers accounted for </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% of gross product revenues; CVS Caremark accounted for </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42%</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of gross product revenues; Pantherx accounted for </span>33<span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% of gross product revenues; and Accredo accounted for </span>25<span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of gross product revenues.</span></p> <p style="margin-bottom:0pt;margin-top:1pt;text-indent:6.54%;font-family:Times New Roman;"> </p> <p style="margin-bottom:0pt;margin-top:1pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company depends on a single source supplier for its product and active pharmaceutical ingredient. </p>
CY2021Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4629000
CY2020Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1907000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
9208000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3693000
CY2021Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
712000
CY2020Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
396000
CY2021Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
2361000
CY2020Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
2660000
CY2021Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2013000
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
941000
CY2021Q2 us-gaap Inventory Gross
InventoryGross
5086000
CY2021Q2 us-gaap Inventory Net
InventoryNet
4951000
CY2021Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4629000
CY2020Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1907000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
9208000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3693000
CY2021Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
83561000
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
9285000
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths
18569000
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Rolling Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo
18569000
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Rolling Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree
18569000
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Rolling Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour
18569000
CY2021Q2 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
175000000
CY2020Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
175000000
CY2021Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
21865000
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
12657000
CY2021Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
153135000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
162343000
CY2019Q3 hrmy License Agreement Milestone Payments Paid
LicenseAgreementMilestonePaymentsPaid
2000000
CY2019Q4 hrmy License Agreement Milestone Payments Paid
LicenseAgreementMilestonePaymentsPaid
75000000
CY2019Q3 hrmy License Agreement Additional Milestone Payments Due
LicenseAgreementAdditionalMilestonePaymentsDue
102000000
CY2019Q3 hrmy Licensing Agreement Milestone Fees
LicensingAgreementMilestoneFees
2000000
CY2021Q1 hrmy License Agreement Milestone Payments Due
LicenseAgreementMilestonePaymentsDue
100000000
CY2021Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
11811000
CY2020Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
9006000
CY2021Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
11811000
CY2020Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
9006000
CY2021Q2 hrmy Accrued Rebates And Other Sales Deductions Current
AccruedRebatesAndOtherSalesDeductionsCurrent
10173000
CY2020Q4 hrmy Accrued Rebates And Other Sales Deductions Current
AccruedRebatesAndOtherSalesDeductionsCurrent
7803000
CY2021Q2 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
1472000
CY2020Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
1905000
CY2021Q2 hrmy Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
1280000
CY2020Q4 hrmy Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
2186000
CY2021Q2 hrmy Accrued Professional Fees Consulting And Other Services
AccruedProfessionalFeesConsultingAndOtherServices
1067000
CY2020Q4 hrmy Accrued Professional Fees Consulting And Other Services
AccruedProfessionalFeesConsultingAndOtherServices
1081000
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
850000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
746000
CY2020Q4 hrmy Accrued Milestone Payment Current
AccruedMilestonePaymentCurrent
100000000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
26653000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
122727000
CY2021Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
217000
us-gaap Operating Lease Expense
OperatingLeaseExpense
353000
CY2020Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
151000
us-gaap Operating Lease Expense
OperatingLeaseExpense
355000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
267000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
875000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
892000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
334000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2368000
CY2019 us-gaap Dividends Preferred Stock
DividendsPreferredStock
0
CY2020Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-8.215
CY2020Q3 us-gaap Preferred Stock Conversion Basis
PreferredStockConversionBasis
1-for-8.215
us-gaap Common Stock Voting Rights
CommonStockVotingRights
one vote for each share
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5210832
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
17.66
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1298690
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
34.90
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
124461
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
8.22
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
301278
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
21.81
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6083783
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
21.32
hrmy Share Based Compensation Expense Income
ShareBasedCompensationExpenseIncome
-10000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.6000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
12.24
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.06
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
936000
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.34
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.38
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.63
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.24
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.34
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.37
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3807000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
461000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7058000
CY2020Q4 hrmy Future Share Based Compensation Expenses Remainder Of Fiscal Year
FutureShareBasedCompensationExpensesRemainderOfFiscalYear
9584000
CY2020Q4 hrmy Future Share Based Compensation Expense Year One
FutureShareBasedCompensationExpenseYearOne
17682000
CY2020Q4 hrmy Future Share Based Compensation Expense Year Two
FutureShareBasedCompensationExpenseYearTwo
16695000
CY2020Q4 hrmy Future Share Based Compensation Expense Year Three
FutureShareBasedCompensationExpenseYearThree
15716000
CY2020Q4 hrmy Future Share Based Compensation Expense Year Four
FutureShareBasedCompensationExpenseYearFour
6046000
CY2020Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
438000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
14117000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-27000
us-gaap Net Income Loss
NetIncomeLoss
21503000
us-gaap Net Income Loss
NetIncomeLoss
-38647000
CY2020Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
10446000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
20891000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
14117000
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10473000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
21503000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-59538000
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.63
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56940840
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7805848
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56916282
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7798928
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58592876
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7805848
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58635195
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7798928
CY2021Q2 hrmy Securities Outstanding Included In Computation Of Utilizing Treasury Stock Method
SecuritiesOutstandingIncludedInComputationOfUtilizingTreasuryStockMethod
1652036
hrmy Securities Outstanding Included In Computation Of Utilizing Treasury Stock Method
SecuritiesOutstandingIncludedInComputationOfUtilizingTreasuryStockMethod
1718912
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4951280
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
41965197
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4884403
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
41965197
CY2020Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
438000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1584000

Files In Submission

Name View Source Status
0001564590-21-042897-index-headers.html Edgar Link pending
0001564590-21-042897-index.html Edgar Link pending
0001564590-21-042897.txt Edgar Link pending
0001564590-21-042897-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gi0tenk51hnl000001.jpg Edgar Link pending
hrmy-10q_20210630.htm Edgar Link pending
hrmy-10q_20210630_htm.xml Edgar Link completed
hrmy-20210630.xsd Edgar Link pending
hrmy-20210630_cal.xml Edgar Link unprocessable
hrmy-20210630_def.xml Edgar Link unprocessable
hrmy-20210630_lab.xml Edgar Link unprocessable
hrmy-20210630_pre.xml Edgar Link unprocessable
hrmy-ex101_170.htm Edgar Link pending
hrmy-ex102_391.htm Edgar Link pending
hrmy-ex103_392.htm Edgar Link pending
hrmy-ex311_168.htm Edgar Link pending
hrmy-ex312_169.htm Edgar Link pending
hrmy-ex321_166.htm Edgar Link pending
hrmy-ex322_167.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending